
Errata

Achenbach P, Warncke K, Reiter J, Naserke HE, Williams AJK, Bingley PJ, Bonifacio E, Ziegler A-G: Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. *Diabetes* 53:384–392, 2004

In Fig. 4 of the above-listed article, three column heads (“A. Total cohort,” “B. Single antibody,” and “C. Multiple antibodies”) were inadvertently deleted. The correct Fig. 4 appears on the following page.




FIG. 4. The cumulative risk of diabetes in autoantibody-positive relatives classified on the basis of islet autoantibody characteristics. Stratification is shown for the total cohort (A), for the 100 relatives with one islet autoantibody (B), and for the 80 relatives with two or more islet autoantibodies (C). Model 1 shows stratification of relatives by the number of islet autoantibodies (A = one autoantibody, B = any two autoantibodies, C = all three autoantibodies). Model 2 shows stratification of relatives by their autoantibody titer and subclass (A = none, B = one, C = two, and D = all three of high titer IA-2A, positivity for IgG2 or IgG4 IA-2A, and positivity for IgG2, IgG3, or IgG4 IAA). Model 3 shows stratification of relatives by their autoantibody titer (A = none, B = one, C = both of high titer IA-2A or high titer IAA). Model 4 shows stratification of relatives by their IA-2A and IA-2 β autoantibody status (A = IA-2A negative, B = IA-2A positive/IA-2 β autoantibody negative, C = IA-2 β autoantibody positive).

Mathews CE, Bagley R, Leiter EH: ALS/Lt: a new type 2 diabetes mouse model associated with low free radical scavenging potential. *Diabetes* 53 (Suppl. 1):S125–S129, 2004

Because it is difficult to distinguish the line graphs in Figs. 2–4 of the above-listed article, the following new figures are provided.




FIG. 2. IGT develops early in ALS/Lt males and worsens with age (A). In comparison, males of the closely related ALR/Lt strain do not exhibit glucose intolerance (B).

FIG. 3. ALS/Lt males exhibit insulin resistance. A: Alloxan-treated ALS males show strong resistance to insulin. Alloxan-treated (52 mg/kg) ALS males (solid line) and females (broken line) were treated with 1 unit porcine insulin 7 days after AL administration. One hour later, a blood sample was drawn to test plasma glucose. Figure 3A is the only experiment included in this study where mice were treated with AL. B: ALS/Lt males spontaneously develop hyperinsulinemia and present with insulin resistance as early as 10 weeks of age. Plasma insulin levels were monitored in unmanipulated ALS/Lt and ALR/Lt males from 4 to 52 weeks of age.






FIG. 4. Daily LA treatment of ALS/Lt males inhibits progression of type 2 diabetes, reducing body weight (A), plasma glucose levels (B), and increasing the levels of circulating reduced GSH (C). Ten ALS/Lt males were randomized into two groups ($n = 5$ per group) either receiving 30 mg/kg of LA (dashed line) or vehicle alone (solid line). Over the following 8 weeks, significant differences were measured at both 14 and 18 weeks of age in plasma glucose and reduced GSH concentrations ($P < 0.05$).